NF-kappaB and ZBP-89 Regulate MMP-3 Expression Via a Polymorphic Site in the Promoter

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2009 Mar 12

PMID 19275880

Citations 13

Authors

Ruth C Borghaei

Grzegorz Gorski

Masoud Javadi

Affiliations

Soon will be listed here.

Abstract

A 5T/6T polymorphism in the human MMP-3 promoter affects gene expression and impacts the risk and/or severity of various pathological conditions. Chromatin immunoprecipitation (ChIP) in human fibroblasts homozygous for the 6T site demonstrate that it is bound by NF-kappaB and ZBP-89 transcription factors in its native chromatin. ChIP in COS-1 cells transfected with plasmids containing the 5T and 6T sites in the context of 2kb of the MMP-3 promoter showed that NF-kappaB p50 binds preferentially to the 6T site, while more ZBP-89 binding is detected to the 5T site. Over-expressed ZBP-89 increased transcription from the 5T promoter but not from the 6T, while NF-kappaB decreased transcription from both promoters, even in the presence of excess ZBP-89. A model is suggested in which the physiological impact of the polymorphism is dependent on the relative levels and activities of these competing factors in various cell types and conditions.

Citing Articles

Interleukin-1β triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells.

Nunomura J, Nakano R, Naruke A, Suwabe Y, Nakano M, Yachiku N PLoS One. 2022; 17(11):e0278220.

PMID: 36445856 PMC: 9707762. DOI: 10.1371/journal.pone.0278220.

Genetic Variants of Matrix Metalloproteinase and Sepsis: The Need Speed Study.

Fiotti N, Mearelli F, Di Girolamo F, Castello L, Nunnari A, Di Somma S Biomolecules. 2022; 12(2).

PMID: 35204780 PMC: 8961575. DOI: 10.3390/biom12020279.

CCL5/CCR5 axis in human diseases and related treatments.

Zeng Z, Lan T, Wei Y, Wei X Genes Dis. 2021; 9(1):12-27.

PMID: 34514075 PMC: 8423937. DOI: 10.1016/j.gendis.2021.08.004.

Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression.

Hsieh C, Liu C, Chen H, Yang S, Shigemura K, Kitagawa K Sci Rep. 2017; 7(1):9065.

PMID: 28831065 PMC: 5567216. DOI: 10.1038/s41598-017-08835-9.

Early Secretory Antigenic Target-6 Drives Matrix Metalloproteinase-10 Gene Expression and Secretion in Tuberculosis.

Brilha S, Sathyamoorthy T, Stuttaford L, Walker N, Wilkinson R, Singh S Am J Respir Cell Mol Biol. 2016; 56(2):223-232.

PMID: 27654284 PMC: 5359650. DOI: 10.1165/rcmb.2016-0162OC.

References

Meijer M, Mieremet-Ooms M, van Hogezand R, Lamers C, Hommes D, Verspaget H . Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007; 13(21):2960-6. PMC: 4171149. DOI: 10.3748/wjg.v13.i21.2960. View

Takahashi M, Haro H, Wakabayashi Y, Kawa-Uchi T, Komori H, Shinomiya K . The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J Bone Joint Surg Br. 2001; 83(4):491-5. DOI: 10.1302/0301-620x.83b4.11617. View

Okamoto K, Mimura K, Murawaki Y, Yuasa I . Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J Gastroenterol Hepatol. 2005; 20(7):1102-8. DOI: 10.1111/j.1440-1746.2005.03860.x. View

Bai L, Merchant J . Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem. 2000; 275(39):30725-33. DOI: 10.1074/jbc.M004249200. View

Mora B, Bonamico M, Ferri M, Megiorni F, Osborn J, Pizzuti A . Association of the matrix metalloproteinase-3 (MMP-3) promoter polymorphism with celiac disease in male subjects. Hum Immunol. 2005; 66(6):716-20. DOI: 10.1016/j.humimm.2005.02.005. View

Bai L, Merchant J . ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol. 2001; 21(14):4670-83. PMC: 87140. DOI: 10.1128/MCB.21.14.4670-4683.2001. View

Borghaei R, Sullivan C, Mochan E . Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3). J Biol Chem. 1999; 274(4):2126-31. PMC: 1595537. DOI: 10.1074/jbc.274.4.2126. View

Medley T, Kingwell B, Gatzka C, Pillay P, Cole T . Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 2003; 92(11):1254-61. DOI: 10.1161/01.RES.0000076891.24317.CA. View

White A, Duffy S, Walton A, Ng J, Rice G, Mukherjee S . Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease. Cardiovasc Res. 2007; 75(4):813-20. DOI: 10.1016/j.cardiores.2007.05.003. View

10.

Nanni S, Melandri G, Hanemaaijer R, Cervi V, Tomasi L, Altimari A . Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res. 2007; 149(3):137-44. DOI: 10.1016/j.trsl.2006.09.001. View

11.

Holliday D, Hughes S, Shaw J, Walker R, Jones J . Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res. 2007; 9(5):R67. PMC: 2242664. DOI: 10.1186/bcr1775. View

12.

Zhu C, Odeberg J, Hamsten A, Eriksson P . Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun. 2006; 348(3):1150-6. DOI: 10.1016/j.bbrc.2006.07.174. View

13.

Beyzade S, Zhang S, Wong Y, Day I, Eriksson P, Ye S . Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol. 2003; 41(12):2130-7. DOI: 10.1016/s0735-1097(03)00482-0. View

14.

Lijnen H, Arza B, Van Hoef B, Collen D, Declerck P . Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J Biol Chem. 2000; 275(48):37645-50. DOI: 10.1074/jbc.M006475200. View

15.

Ye S, Whatling C, Watkins H, Henney A . Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett. 1999; 450(3):268-72. DOI: 10.1016/s0014-5793(99)00509-8. View

16.

Bond M, Chase A, Baker A, Newby A . Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res. 2001; 50(3):556-65. DOI: 10.1016/s0008-6363(01)00220-6. View

17.

Nowak D, Tian B, Brasier A . Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques. 2005; 39(5):715-25. DOI: 10.2144/000112014. View

18.

Bai L, Logsdon C, Merchant J . Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer. Int J Gastrointest Cancer. 2003; 31(1-3):79-88. DOI: 10.1385/IJGC:31:1-3:79. View

19.

Liu P, Li Y, Tsai W, Tsai L, Chao T, Wu H . Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction. J Thromb Haemost. 2005; 3(9):1998-2005. DOI: 10.1111/j.1538-7836.2005.01515.x. View

20.

Samnegard A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J . Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med. 2005; 258(5):411-9. DOI: 10.1111/j.1365-2796.2005.01561.x. View